Molecular Imaging of Newly Diagnosed Prostate Cancer

被引：4

作者：

Williams, Scott ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Div Radiat Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Univ Melbourne, Div Radiat Oncol, Melbourne, Vic, Australia

来源：

CANCER JOURNAL | 2020年 / 26卷 / 01期

关键词：

Positron emission tomography; prostate cancer; prostate-specific membrane antigen; POSITRON-EMISSION-TOMOGRAPHY; MEMBRANE ANTIGEN-EXPRESSION; GA-68-PSMA PET/CT; C-11-CHOLINE PET/CT; METASTASES; CARCINOMA; ACID; VALIDATION; RECURRENCE; ACCURACY;

D O I：

10.1097/PPO.0000000000000427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron emission tomography (PET) is a valuable imaging in evaluating many malignancies. There are various molecular imaging tracers that are currently being utilized with prostate cancer (PC). Several PET agents imaging different molecular processes in PC have reached the clinic. While all of these agents have demonstrated an advantage over conventional imaging, there are considerable differences in the performance of each in staging newly diagnosed PC. In this article, we review the current updates available of different PET tracers, with a strong focus on the emerging role of prostate-specific membrane antigen PET in the management of newly diagnosed PC.

引用

页码：43 / 47

页数：5

共 50 条

[21] Colorectal Cancer Screening Among Men With Newly Diagnosed Prostate Cancer
Leachman, Brooke K.
Scharf, Lawrence J.
Sobczak, Mark L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E7 - E7
[22] Breast MR Imaging in Newly Diagnosed Breast Cancer
Gupta, Dipti
Billadello, Laura
RADIOLOGIC CLINICS OF NORTH AMERICA, 2017, 55 (03) : 541 - +
[23] How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come
Schilham, Melline G. M.
Rijpkema, Mark
Scheenen, Tom
Hermsen, Rick
Barentsz, Jelle O.
Sedelaar, J. P. Michiel
Kusters-Vandevelde, Heidi
Kerkmeijer, Linda G. W.
Somford, Diederik M.
Gotthardt, Martin
EUROPEAN UROLOGY, 2022, 82 (06) : 578 - 580
[24] Guideline-Discordant Use of Imaging During Work-Up of Newly Diagnosed Prostate Cancer
Falchook, Aaron D.
Hendrix, Laura H.
Chen, Ronald C.
JOURNAL OF ONCOLOGY PRACTICE, 2015, 11 (02) : E239 - E246
[25] Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb, Stacy
Giri, Veda N.
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (01): : 1 - 9
[26] PROVIDER INTERACTIONS WITH PARTNERS OF MEN NEWLY DIAGNOSED WITH PROSTATE CANCER
Zeliadt, Steven
Penson, David F.
Moinpour, Arol M.
Blough, David K.
Fedorenko, Catherine R.
Hall, Ingrid J.
Smith, Judith Lee
Ekwueme, Donatus
Thompson, Ian M.
Keane, Thomas E.
Ramsey, Scott D.
ANNALS OF BEHAVIORAL MEDICINE, 2010, 39 : 5 - 5
[27] The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis
Albertsen, PC
Hanley, JA
Harlan, LC
Gilliland, FD
Hamilton, A
Liff, JM
Stanford, JL
Stephenson, RA
JOURNAL OF UROLOGY, 2000, 163 (04): : 1138 - 1143
[28] New developments in the management of newly diagnosed metastatic prostate cancer
Leone, Gianmarco
Alifrangis, Constantine
TRENDS IN UROLOGY & MENS HEALTH, 2023, 14 (03) : 6 - 9
[29] Current health utility of newly diagnosed prostate cancer patients
Miles, BJ
Fearn, PA
Hu, JC
Cowen, ME
Giesler, RB
Kattan, MW
JOURNAL OF UROLOGY, 1998, 159 (05): : 258 - 258
[30] Multidisciplinary Therapy in Men with Newly Diagnosed Oligometastatic Prostate Cancer
Watanabe, Kazuhiro
Kawaguchi, Gen
Ikeda, Yohei
Hara, Noboru
Nishiyama, Tsutomu
RESEARCH AND REPORTS IN UROLOGY, 2021, 13 : 565 - 571

← 1 2 3 4 5 →